Overriding Elements in Colon Cancer Progression: Some Less Known Facts
DOI:
https://doi.org/10.17140/GOJ-2-124Keywords:
Colon cancer, Apoptosis, Chemokines, Inflammasomes, InflammationAbstract
Colorectal cancer (CRC) is one of the most life threatening disease with escalating mortality and morbidity. Some known causative factors include lifestyle, alcohol etc. but there are other aspects like long standing colitis, inhibition of apoptotic proteins, chemokines and their receptors and inflammasomes which increase the chances of CRC progression. In a clinical setting of diseases like colitis and Crohn’s disease, the risk of CRC varies on degree of inflammation, expression of chemokines and cytokines and other molecular alterations. Hence, the underlying molecular inductions determine the fate of CRC progression through extent of epithelial mesenchymal transition, metastasis and invasive ability. The present view point will showcase some of the latent and notable considerations in CRC progression.
References
Dekker E, Gulik TV. Colorectal cancer: What the clinician wants to know. Cancer Imaging. 2005; 5: S127-S132. doi: 10.1102/1470-7330.2005.0036
Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal can-cer and inflammatory bowel disease: Epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anti-cancer Res. 2009; 29: 2727-2738. Web site. http://ar.iiarjournals. org/content/29/7/2727.long. Accessed July 3, 2016
Clevers H. Colon cancer-understanding how NSAIDs work. N Engl J Med. 2006; 354: 761-763. doi: 10.1056/NEJMcibr055457
Schottelius AJ, Dinter H. Cytokines, NF-ÎB, microenviron-ment, intestinal inflammation and cancer. Cancer Treat Res. 2006; 130: 67-87. doi: 10.1007/0-387-26283-0_3
Yan B, Wang H, Rabbani ZN, et al. Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res. 2006; 66(24): 11565-11570. doi: 10.1158/0008-5472.CAN-06-2540
Müller-Edenborn K, Léger K, Garzon JFG, et al. Hypoxia attenuates the proinflammatory response in colon cancer cells by regulating IκB. Oncotarget. 2015; 6(24): 20288-20301. doi: 10.18632/oncotarget.3961
Hongo K, Nelson Tsuno H, Kawai K. Hypoxia enhances co-lon cancer migration and invasion through promotion of epithe-lial-mesenchymal transition. J Surg Res. 2013; 182: 75-84. doi: 10.1016/j.jss.2012.08.034
Luo X, Jinke Yao H, Nie P. FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation. Oncotarget. 2016; 7(18): 26480-26495. doi: 10.18632/oncotarget.8419
Ghadjar P, Rubie C, Aebersold DM, et al. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 2009; 125(4): 741-745. doi:
1002/ijc.24468 10. Gunther K, Leier J, Henning G, et al. Prediction of lymph node metastasis in colorectal carcinoma by expression of che-mokine receptor CCR7. Int J Cancer. 2005; 116: 726-733. doi: 10.1002/ijc.21123
Kapur N, Mir H, Clark Iii CE, et al. CCR6 expression in co-lon cancer is associated with advanced disease and supports ep-ithelial-to-mesenchymal transition. Br J Cancer. 2016; 114(12): 1343-1351. doi: 10.1038/bjc.2016.113
Rubie C, Oliveira V, Kempf K, et al. Involvement of chemo-kine receptor CCR6 in colorectal cancer metastasis. Tumor Biol. 2006; 27: 166-174. doi: 10.1159/000092777
Kawada K, Hosogi H, Sonoshita M. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. On-cogene. 2007; 26(32): 4679-4688. doi: 10.1038/sj.onc.1210267
Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: An update. Oncotarget. 2013; 5(1): 49-66. doi: 10.18632/ oncotarget.1548
Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer. 2010; 9: 57. doi: 10.1186/1476-4598-9-57
Gulhati P, Cai Q, Li J, et al. Targeted inhibition of mam-malian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res. 2009; 15(23): 7207-7216. doi: 10.1158/1078-0432.CCR-09-1249
Gulhati P, Bowen KA, Liu J, et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011; 71(9): 3246-3256. doi: 10.1158/0008-5472.CAN-10-4058
Mukherjee B, Tomimatsu N, Amancherla K, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neo-plasia. 2012; 14(1): 34-43. doi: 10.1593/neo.111512
Allen IC, TeKippe EM, Woodford RM, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigen-esis during colitis-associated cancer. J Exp Med. 2010; 207(5): 1045-1056. doi: 10.1084/jem.20100050
Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010; 32(3): 379-391. doi: 10.1016/j.immu-ni.2010.03.003
Zaki MH, Lamkanfi M, Kanneganti T-D. The Nlrp3 inflam-masome in IBD and colorectal tumorigenesis. Trends Immunol. 2011; 32(4): 171-179. doi: 10.1016/j.it.2011.02.002
Dupaul-Chicoine J, Arabzadeh A, Dagenais M, et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity. 2015; 43(4): 751-763. doi: 10.1016/j.immu-ni.2015.08.013
Tiwari K, Pandey SK, Goel S. SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expres-sion. Oncogenesis. 2015; 4: e162. doi: 10.1038/oncsis.2015.23
Chen Y-T, Tsao S-C, Shyng-Shiouvyuan F. Serine prote-ase inhibitor kazal type 1 (SPINK1) promotes proliferation of colorectal cancer through the epidermal growth factor as a prognostic marker. Pathol Oncol Res. 2015; 21: 1201-1208. doi: 10.1007/s12253-015-9949-0
Chen Y-T, Tsao S-C, Tsai H-P. Serine protease inhibitor kazal type 1 (SPINK1) as a prognostic marker in stage IV colon can-cer patients receiving cetuximab based targeted therapy. J Clin Pathol. 2016; 1-5. doi: 10.1136/jclinpath-2016-203638
Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorec-tal cancer. Cancer Metastasis Rev. 2004; 23: 63-75. doi: 10.1023/A:1025863029529
Wang D, Raymond Dubois N. The role of COX-2 in intesti-nal inflammation and colorectal cancer. Oncogene. 2011; 29(6): 781-788. doi: 10.1038/onc.2009.421
Li M, Wu X, Xu X-C. Induction of apoptosis in colon can-cer cells by cyclooxygenase-2 inhibitor NS398 through a cy-tochrome c-dependent pathway. Clin Cancer Res. 2001; 7: 1010-1016. Web site. http://clincancerres.aacrjournals.org/con-tent/7/4/1010.long. Accessed July 3, 2016
Sheehan KM, Sheahan K, O’Donoghue DP, et al. The re-lationship between cyclooxygenase-2 expression and colorec-tal cancer. JAMA. 1999; 282(13): 1254-1257. doi: 10.1001/ jama.282.13.1254
Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclo-oxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in hu-man colon cancer cells. Cancer Res. 2002; 62(21): 6323-6328. Web site. http://cancerres.aacrjournals.org/content/62/21/6323. full-text.pdf. Accessed July 3, 2016
Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxy-genase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apopto-sis- inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002; 62(17): 4903-4908. Web site. http:// cancerres.aacrjournals.org/content/62/17/4903.full-text.pdf. Ac-cessed July 3, 2016
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Gastro (GOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.